Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | PD-1 blockade after progression on bispecific CAR-T therapy in R/R B-cell malignancies

Joanna Zurko • 14 Apr 2022
The 2022 Tandem Meetings
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Pembrolizumab

Joanna Zurko, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of a study investigating the efficacy of PD-1 blockade after failure of bispecific anti-CD20, anti-CD19 CAR-T therapy in patients with R/R B-cell malignancies. Overall, the study suggested that treatment with pembrolizumab did not lead to sustained response to treatment, but further studies are required to confirm these findings. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Joanna Zurko

1:41
Copper deficiency and the importance of differential diagnosis in MDS
Joanna Zurko • 14 Apr 2022
3:44
AlloHSCT for R/R LBCL after CAR-T therapy failure
Joanna Zurko • 14 Apr 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals